Meeting
2018 ASCO Annual Meeting
18F-Fluoroestradiol (FES) and 18F-Fluorodeoxyglucose (FDG) PET imaging in lobular breast cancer.
Authors
Poorni Manohar
University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA
Poorni Manohar , Lanell Peterson , Vicky Wu , Isaac Jenkins , Alena Novakova-Jiresova , Jennifer M. Specht , Jeanne Link , Kenneth A. Krohn , Paul Kinahan , David A. Mankoff , Hannah M. Linden
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 36, 2018 (suppl; abstr 1063)
DOI
10.1200/JCO.2018.36.15_suppl.1063
Abstract #
1063
Poster Bd #
144
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Matched FES and FDG PET imaging in patients with hormone receptor-positive, HER2+ advanced breast cancer.
First Author: Natasha Hunter
Poster
2017 ASCO Annual Meeting
The use of 18F-fluoroestradiol (FES) and 18F-fluorodeoxyglucose (FDG) PET in the evaluation of breast cancer heterogeneity.
First Author: Lanell M Peterson
Poster
2016 ASCO Annual Meeting
Androgen receptor and estrogen receptor imaging in patients with metastatic breast cancer.
First Author: Clasina Marieke Venema
Poster
2023 ASCO Annual Meeting
Prospective evaluation of the utility of concurrent 18F-FDG PET/CT and 68Ga-DOTA-TOC imaging in gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): The PETNET study.
First Author: Joao Paulo Solar Vasconcelos